KRAS and pancreatic ductal adenocarcinoma: While the specific frequencies reported varies by source, activating mutations in KRAS are present in approximately 25-30% of NSCLC (6, 7), 80-95% of pancreatic ductal adenocarcinoma (PDAC) (8, 9) and 40-50% of CRC (9, 10) (Figure 1).